Eversept Partners’s Pliant Therapeutics PLRX Stock Holding History

Eversept Partners’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Hold	891,425	–	–	0.05%	105
2026 Q1	$1.12M	Buy	891,425 +49,402	+6%	+$62.4K	0.06%	104
2025 Q4	$1.03M	Buy	842,023 +17,429	+2%	+$26.2K	0.05%	98
2025 Q3	$1.22M	Buy	+824,594	New	+$1.26M	0.08%	75
2023 Q1	–	Sell	-137,423	Closed	-$2.66M	–	75
2022 Q4	$2.66M	Sell	137,423 -156,680	-53%	-$3.28M	0.23%	45
2022 Q3	$6.14M	Buy	+294,103	New	+$5.63M	0.53%	36

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Eversept Partners's PLRX Position: Q2 2026 in Review

Eversept Partners held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 891,425 shares worth $1.02M. The position accounts for 0.05% of the portfolio, ranked #105.

Eversept Partners first reported a position in PLRX in Q3 2022 and has held it in 6 quarters since. The position peaked at $6.14M in Q3 2022. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Eversept Partners held 891,425 shares of Pliant Therapeutics worth $1.02M as of Q2 2026.
Eversept Partners left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up 0.05% of Eversept Partners's portfolio in Q2 2026, its #105 holding.
Eversept Partners first reported a position in Pliant Therapeutics in Q3 2022 and has held it in 6 quarters since.
Eversept Partners's Pliant Therapeutics position peaked at $6.14M in Q3 2022.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.